Candel Therapeutics (CADL) Cash from Operations (2020 - 2023)
Historic Cash from Operations for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$7.4 million.
- Candel Therapeutics' Cash from Operations fell 779.96% to -$7.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$34.2 million, marking a year-over-year decrease of 899.14%. This contributed to the annual value of -$27.0 million for FY2024, which is 2108.69% up from last year.
- Candel Therapeutics' Cash from Operations amounted to -$7.4 million in Q4 2023, which was down 779.96% from -$8.8 million recorded in Q3 2023.
- In the past 5 years, Candel Therapeutics' Cash from Operations registered a high of -$1.5 million during Q3 2020, and its lowest value of -$10.8 million during Q1 2023.
- Over the past 4 years, Candel Therapeutics' median Cash from Operations value was -$7.0 million (recorded in 2021), while the average stood at -$6.6 million.
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 35807.31% in 2021, then skyrocketed by 613.81% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Cash from Operations stood at -$3.4 million in 2020, then plummeted by 53.34% to -$5.2 million in 2021, then tumbled by 31.44% to -$6.9 million in 2022, then decreased by 7.8% to -$7.4 million in 2023.
- Its last three reported values are -$7.4 million in Q4 2023, -$8.8 million for Q3 2023, and -$7.2 million during Q2 2023.